Emc Capital Management Chemo Centryx, Inc. Transaction History

Emc Capital Management

$178 Million
Q4 2024

Shares

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2022 May 16, 2022	SELL	$22.22 - $39.12 $464,886 - $818,468	-20,922 Closed	0 $0
Q4 2021 Feb 10, 2022	BUY	$18.38 - $40.5 $384,546 - $847,341	20,922 New	20,922 $762,000
Q3 2021 Nov 02, 2021	SELL	$13.18 - $19.83 $93,248 - $140,297	-7,075 Closed	0 $0
Q2 2021 Aug 09, 2021	SELL	$9.59 - $50.88 $9,925 - $52,660	-1,035 Reduced 12.76%	7,075 $95,000
Q1 2021 May 05, 2021	SELL	$49.53 - $68.4 $40,218 - $55,540	-812 Reduced 9.1%	8,110 $416,000
Q4 2020 Feb 24, 2021	BUY	$47.25 - $65.16 $421,564 - $581,357	8,922 New	8,922 $552,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Emc Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Emc Capital Management with notifications on news.